Form 4: AIM ImmunoTech Director Acquires Shares in Unintended Transaction

A director of AIM ImmunoTech Inc. unintentionally acquired shares of common stock in a recent transaction.

Summary

• Stewart Appelrouth, a director at AIM ImmunoTech Inc., acquired shares of common stock on December 2, 2024.
• The director purchased 1 share at $0.212 and then another 11,111 shares at the same price.
• Following these transactions, Mr. Appelrouth directly owns 355,509 shares of AIM ImmunoTech Inc. common stock.
• The director stated that the initial purchase of 1 share was not intended.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider transaction. The unintended nature of the initial purchase is slightly negative, but overall the document is neutral.

Management Comments

• The reporting person did not intend this purchase.

Industry Context

This is a standard SEC Form 4 filing, which is required when company insiders trade shares. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The transaction is a routine disclosure of insider trading activity and is comparable to similar filings by other companies.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small purchase by a director.

Key Dates

Keywords

AIM ImmunoTech, insider trading, share acquisition, director, common stock, ownership